Latest & greatest articles for atrial fibrillation

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on atrial fibrillation or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on atrial fibrillation and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for atrial fibrillation

861. Preventing stroke in patients with atrial fibrillation

Preventing stroke in patients with atrial fibrillation Preventing stroke in patients with atrial fibrillation Preventing stroke in patients with atrial fibrillation Ezekowitz M D, Levine J A Authors' objectives To assess the evidence supporting the use of warfarin and/or aspirin for stroke prevention in patients with atrial fibrillation. Searching The authors searched the electronic MEDLINE database (January 1, 1966 to February 23, 1999) using the search terms: 'atrial fibrillation', 'stroke (...) and aspirin in combination study. Follow-up is not reported for the warfarin versus aspirin studies. Specific interventions included in the review Warfarin (dosages not stated), or aspirin (75 to 325 mg/day), or low- intensity fixed-dose warfarin-aspirin combination (with International Normalised Ratio (INR) of 1.2 to 1.5) versus adjusted dose warfarin (with INR 2.0 to 3.0), or placebo. Participants included in the review Patients with atrial fibrillation. Patients in the 5 primary studies who required

1999 DARE.

862. Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery

Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Cost-effectiveness of amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery Reddy P, Richerson M, Freeman-Bosco L, Dunn A, White C M, Chow M S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Amiodarone for prophylaxis of atrial fibrillation in coronary artery bypass surgery. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients undergoing CABG. Setting The setting was hospital

1999 NHS Economic Evaluation Database.

863. Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis

Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis Cardioversion in patients with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis Cardioversion in patients (...) with atrial fibrillation and left atrial thrombi on initial transesophageal echocardiography: should transesophageal echocardiography be repeated before elective cardioversion? A cost-effectiveness analysis Seto T B, Taira D A, Manning W T Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability

1999 NHS Economic Evaluation Database.

864. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation

Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation Catherwood E, Fitzpatrick W D, Greenberg M L, Holzberger P T, Malenka D J, Gerling B R, Birkmeyer J D Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Cardioversion, with or without antiarrhythmic agents, versus rate control and antithrombotic therapy for treatment of patients with nonvalvular atrial fibrillation. Type of intervention Secondary prevention. Economic study type Cost-utility analysis. Study population Hypothetical

1999 NHS Economic Evaluation Database.

865. Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation

Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation Comparison of sotalol versus quinidine for maintenance of normal sinus rhythm in patients with chronic atrial fibrillation Southworth M R, Zarembski D, Viana M, Bauman J Authors' objectives To compare the efficacy and safety of quinidine, sotalol (...) , and control in maintaining normal sinus rhythm (SR) in patients with chronic atrial fibrillation (AF). Searching The authors searched the electronic MEDLINE database from 1985 to present, the search term 'sotalol' was crossed with 'atrial fibrillation' and 'atrial flutter', and the results of this search were crossed with the search term 'clinical trial'. An additional search from 1990 to present used the search term 'quinidine'. A previous meta-analysis was included in the search for additional studies

1999 DARE.

866. Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis

Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis Propafenone for the treatment of supraventricular tachycardia and atrial fibrillation: a meta-analysis Reimold S C, Maisel W H, Antman E M Authors' objectives To determine propafenone's effectiveness in terminating and suppressing supraventricular arrhythmias using meta-analytic techniques (...) reduction in frequency, severity, or duration of episodes as end points in paroxysmal AF, were included in the text of the review but not formally combined. Randomised and non-randomised controlled trials were included in the review. Specific interventions included in the review Intravenous (2mg/kg initial bolus +/- infusion) and oral (450,600,900 mg/day) propafenone. Participants included in the review Patients with supraventricular tachycardia or atrial fibrillation, including paroxysmal AF

1998 DARE.

867. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke

Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke Lightowlers S, McGuire A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED (...) . Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Anticoagulation in nonrheumatic atrial fibrillation (NRAF) in the primary prevention of ischemic stroke. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population Patients with NRAF with no contraindication to anticoagulation. Setting Hospital

1998 NHS Economic Evaluation Database.

868. Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation

Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation Gage B F, Cardinalli A B, Owens D K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Antithrombotic therapy for patients with nonvalvular atrial fibrillation. Type of intervention Treatment. Economic study type Cost-utility analysis. Study population Hypothetical 65-year old patients with nonvalvular atrial fibrillation. The base case consisted of a hypothetical cohort whose members had

1998 NHS Economic Evaluation Database.

869. Electrical cardioversion of atrial fibrillation or flutter with conscious sedation in the age of cost containment

Electrical cardioversion of atrial fibrillation or flutter with conscious sedation in the age of cost containment Electrical cardioversion of atrial fibrillation or flutter with conscious sedation in the age of cost containment Electrical cardioversion of atrial fibrillation or flutter with conscious sedation in the age of cost containment Goldner B G, Baker J, Accordino A, Sabatino L, DiGiulio M, Kalenderian D, Lin D, Zambrotta V, Stechel J, Maccaro P, Jadonath R Record Status (...) This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The intervention health technology was conscious sedation (benzodiazepine-opioid) administered by certified electrophysiologists during elective cardioversion of atrial fibrillation/atrial flutter to sinus

1998 NHS Economic Evaluation Database.

870. Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. (Abstract)

Preoperative amiodarone as prophylaxis against atrial fibrillation after heart surgery. Atrial fibrillation occurs commonly after open-heart surgery and may delay hospital discharge. The purpose of this study was to assess the use of preoperative amiodarone as prophylaxis against atrial fibrillation after cardiac surgery.In this double-blind, randomized study, 124 patients were given either oral amiodarone (64 patients) or placebo (60 patients) for a minimum of seven days before elective (...) cardiac surgery. Therapy consisted of 600 mg of amiodarone per day for seven days, then 200 mg per day until the day of discharge from the hospital. The mean (+/-SD) preoperative total dose of amiodarone was 4.8+/-0.96 g over a period of 13+/-7 days.Postoperative atrial fibrillation occurred in 16 of the 64 patients in the amiodarone group (25 percent) and 32 of the 60 patients in the placebo group (53 percent) (P=0.003). Patients in the amiodarone group were hospitalized for significantly fewer days

1997 NEJM Controlled trial quality: uncertain

871. The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm

The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm The cost-effectiveness of ibutilide versus electrical cardioversion in the conversion of atrial fibrillation and flutter to normal rhythm Zarkin G A, Bala M V, Calingaert B, VanderLugt J T Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Ibutilide in the conversion of atrial fibrillation and flutter to normal rhythm. Intravenous ibutilide treatment was administered in two 10-minute doses 10 minutes apart. The initial dose was 1 mg and the second dose

1997 NHS Economic Evaluation Database.

872. Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation

Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial fibrillation Cost-effectiveness of transesophageal echocardiographic-guided cardioversion: a decision analytic model for patients admitted to the hospital with atrial (...) fibrillation Seto T B, Taira D A, Tsevat J, Manning W J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Transesophageal Echocardiographic (TEE)-guided cardioversion as a method for early cardioversion of patients with atrial fibrillation

1997 NHS Economic Evaluation Database.

873. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. (Abstract)

Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Adjusted-dose warfarin is highly efficacious for prevention of ischaemic stroke in patients with atrial fibrillation (AF). However, this treatment carries a risk of bleeding and the need for frequent medical monitoring. We sought an alternative that would be safer and easier to administer

1996 Lancet Controlled trial quality: uncertain

874. Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy

Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy Atrial fibrillation: restoration and maintenance of sinus rhythm and indications for anticoagulation therapy Golzari H, Cebul R D, Bahler R C Authors' objectives To review the efficacy and safety of electrical and pharmacological conversion of atrial fibrillation, strategies (...) examined in this context, along with surgical corridor and maze procedures. In addition, antithrombotic therapy is examined, and the effectiveness of warfarin, aspirin and anticoagulants is assessed. Participants included in the review Patients with atrial fibrillation. A small number of studies included patients with fibrillation after cardiac surgery. Outcomes assessed in the review The main outcome was restoration of sinus rhythm. Reduction in incidence of ischaemic stroke and emboli is also

1996 DARE.

875. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. Full Text available with Trip Pro

Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. A number of studies have demonstrated the efficacy of oral anticoagulant therapy in reducing the risk of stroke and systemic embolism in patients with nonrheumatic atrial fibrillation. However, both the targeted and the actual levels of anticoagulation differed widely among the studies, and a number of studies failed to report (...) standardized prothrombin-time ratios as international normalized ratios (INRs). We therefore performed an analysis to determine the intensity of oral anticoagulant therapy in nonrheumatic atrial fibrillation that provides the best balance between the prevention of thromboembolism and the occurrence of bleeding complications.We calculated INR-specific incidence rates for both ischemic and major hemorrhagic events occurring in 214 patients who received anticoagulant therapy in the European Atrial

1995 NEJM Controlled trial quality: uncertain

876. Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation

Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation Anticoagulation for stroke prevention in chronic non-valvular atrial fibrillation Green C J, Hadorn D, Kazanjian A Authors' objectives To assess the evidence concerning the outcomes associated with efforts to prevent the occurrence of stroke in patients with chronic non-valvular atrial fibrillation using warfarin sodium. Searching (...) MEDLINE was searched from 1987 to 1994 using the keywords: 'atrial fibrillation', 'anticoagulants', 'aspirin'). Reference lists of retrieved articles were sought. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) on the efficacy of warfarin sodium in the primary prevention of stroke in chronic non-valvular atrial fibrillation were included. Specific interventions included in the review The specific intervention was anticoagulation, i.e. warfarin

1995 DARE.

877. Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials

Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion from atrial fibrillation and flutter: an analysis of pooled trials Limitations of transesophageal echocardiography in the risk assessment of patients before nonanticoagulated cardioversion (...) from atrial fibrillation and flutter: an analysis of pooled trials Moreyra E, Finkelhor R S, Cebul R D Authors' objectives To compare the embolic risk from the pooled results of transesophageal echocardiography (TEE) trials with that of historical controls with blind cardioversion in anticoagulated or nonanticoagulated participants. Searching MEDLINE was searched from 1966 to 1993 for English language studies using the following search headings: 'transesophageal echocardiography', 'atrial

1995 DARE.

878. Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide

Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Treatment of resistant atrial fibrillation: a meta-analysis comparing amiodarone and flecainide Zarembski D G, Nolan P E, Slack M K, Caruso A C Authors' objectives To compare the efficacies of two antiarrhythmic drug therapies, amiodarone hydrochloride and flecainide acetate, in maintaining normal sinus (...) rhythm in patients with resistant chronic atrial fibrillation. Searching Current Contents: Clinical Practice was reviewed and MEDLINE was searched from January 1983 to August 1993 for English language studies. Bibliographies of identified articles were searched to locate additional articles. Study selection Study designs of evaluations included in the review Prospective clinical trials were included. Specific interventions included in the review Amiodarone hydrochloride and flecainide acetate

1995 DARE.

879. Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis

Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis Antiarrhythmic prophylaxis vs warfarin anticoagulation to prevent thromboembolic events among patients with atrial fibrillation: a decision analysis Middlekauff H R, Stevenson W G, Gornbein J A Authors (...) ' objectives To establish the most efficacious strategy to prevent thromboembolism associated with atrial fibrillation. Searching MEDLINE was searched from 1966 to 1992, using the terms 'quinidine', 'warfarin', or 'amiodarone' with 'atrial fibrillation'. References of retrieved articles were checked. Only English language papers were included. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) with a minimum follow-up of 3 months. For amiodarone therapy

1995 DARE.

880. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation

Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation Gage B, Cardinalli A, Albers G, Owens D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Warfarin sodium, for the prevention of stroke in patients who have nonvalvular atrial fibrillation (NVAF), with or without additional stroke risk factors. Type of intervention Primary prevention and secondary prevention. Economic study type Cost-effectiveness analysis. Study population

1995 NHS Economic Evaluation Database.